EZOGABINE (POTIGA) MACULOPATHY.
To present a case of partially reversible retinal toxicity related to a newer epilepsy medication, ezogabine (Potiga). Case report with multimodal imaging. A patient presented 9 months after starting ezogabine for a screening eye examination with new retinal pigment abnormalities in the maculas of both eyes. These macular abnormalities are characterized for the first time with multimodal imaging. They were partially reversible after cessation of the drug. Ezogabine toxicity presents as pigmentary changes in the macula on fundus examination and has newly described characteristics on imaging that can guide ophthalmologists when they perform the FDA-recommended 6-month screening visits for ocular toxicity.